Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail. Authors' reply.

Hadrien AlricAurélien AmiotFranck CarbonnelAntoine Meyer

Published in: Alimentary pharmacology & therapeutics (2020)

Keyphrases

rheumatoid arthritis

ulcerative colitis

patients with inflammatory bowel disease